MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
18 déc. 2024 07h00 HE
|
MannKind
MANNKIND CORPORATION ANNOUNCES EXCHANGE OF CONVERTIBLE NOTES FOR STOCK AND CASH
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
16 déc. 2024 06h05 HE
|
MannKind
MANNKIND ANNOUNCES SIX-MONTH RESULTS FROM PHASE 3 INHALE-1 PEDIATRIC DIABETES TRIAL UTILIZING INHALED INSULIN (AFREZZA®)
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
11 déc. 2024 06h00 HE
|
MannKind
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
07 nov. 2024 16h02 HE
|
MannKind
MANNKIND CORPORATION REPORTS
2024 THIRD QUARTER FINANCIAL RESULTS AND
PROVIDES BUSINESS UPDATE
MannKind to Present at 2024 UBS Healthcare Conference
05 nov. 2024 16h15 HE
|
MannKind
MannKind to Present at 2024 UBS Healthcare Conference
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
04 nov. 2024 06h05 HE
|
MannKind
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
31 oct. 2024 16h05 HE
|
MannKind
Mannkind Corporation to Hold 2024 Third Quarter
Financial Results Conference Call on November 7, 2024
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
30 oct. 2024 21h00 HE
|
MannKind
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of NTM Lung Disease
More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)
30 sept. 2024 06h00 HE
|
MannKind
MORE ADULTS WITH TYPE 1 DIABETES ACHIEVED A1C GOAL (<7%) AFTER SWITCHING FROM MULTIPLE DAILY INSULIN INJECTIONS
OR AUTOMATED PUMPS TO INHALED INSULIN
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
18 sept. 2024 06h15 HE
|
MannKind
MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical
Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension
for the Treatment